In CRSwNP patients with NSAID-ERD, DUPIXENT improved key measures of disease severity

IN NASAL CONGESTION (NC) SCORE AT WEEK 52 (SINUS‑52: SECONDARY ENDPOINT) with DUPIXENT 300 mg Q2W + INCS (n=35) (-1.34 from a baseline score of 2.38) vs 8% improvement with placebo + INCS (n=44) (-0.21 from a baseline score of 2.49) (LSM difference: -1.13 [95% CI: -1.49, -0.77])

IN NASAL POLYP SCORE (NPS) AT WEEK 52 (SINUS‑52: SECONDARY ENDPOINT)with DUPIXENT 300 mg Q2W + INCS (n=35) (baseline score 5.87) vs 0.03 worsening with placebo + INCS (n=44) (baseline score 6.06) (LSM difference: -2.57 [95% CI: -3.27, -1.87])

IN LMK-CT SCORE AT WEEK 52 (SINUS-52: OTHER SECONDARY ENDPOINT) with DUPIXENT 300 mg Q2W + INCS (n=35) (-7.27 from a baseline score of 19.71) vs 2% improvement with placebo + INCS (n=44) (-0.41 from a baseline score of 19.07) (LSM difference: -6.86 [95% CI: -8.62, -5.10])

Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.